# OnCo record actinium-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/actinium-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "actinium-pharmaceuticals" ;
  schema:name "Actinium Pharmaceuticals"@en ;
  schema:description "Actinium Pharmaceuticals attaches the alpha-emitting isotope actinium-225 to antibodies to treat acute myeloid leukaemia and, more recently, solid tumours such as prostate and lung cancer. It is a small listed company whose lead programme is approaching new clinical milestones."@en ;
  schema:url <https://onco.cc/companies/actinium-pharmaceuticals/>, <https://www.actiniumpharma.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.actiniumpharma.com/>, <https://ir.actiniumpharma.com/press-releases/detail/525/actinium-pharmaceuticals-announces-actimab-a-intellectual>, <https://ir.actiniumpharma.com/press-releases> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/radioimmunotherapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/cd33/> ;
  onco:drugs <https://onco.cc/drugs/iomab-b/> .